Related Experiment Videos
[Clinical studies on aztreonam in perinatal use]
T Chimura1, N Morisaki, T Funayama
1Department of Obstetrics and Gynecology, School of Medicine, Yamagata University.
The Japanese Journal of Antibiotics
|April 1, 1990
Summary
Aztreonam (AZT) effectively treated 91.7% of perinatal infections in a clinical study. This monobactam antibiotic demonstrated excellent safety with no observed side effects in patients.
Area of Science:
- Infectious Diseases
- Pharmacology
- Obstetrics & Gynecology
Background:
- Perinatal infections pose significant risks to mothers and newborns.
- Monobactam antibiotics offer a potential treatment avenue for these infections.
Observation:
- Aztreonam (AZT) was administered via drip infusion (2-4 g/day) to 12 patients with perinatal infections.
- Clinical outcomes and bacteriological data were systematically collected.
- Patient monitoring included assessment for subjective/objective side effects and clinical values.
Findings:
- Aztreonam demonstrated a high efficacy rate of 91.7% (11/12) in treating various perinatal infections.
- Excellent responses were noted for mastitis, pyelonephritis, and urinary tract infections.
- Good responses were observed in cases of amnionitis, amniotic fluid infections, and external genital infections.
- Bacteriological studies showed eradication or replacement of pathogens in several cases.
- One case of cervicitis complicated with amnionitis showed non-effectiveness with MIC values of 25- >100 µg/ml.
- No adverse events or abnormal clinical values were reported during AZT treatment.
Implications:
- Aztreonam is a safe and effective therapeutic option for managing perinatal infections.
- Further research may explore optimal dosing and specific indications for aztreonam in obstetric care.
- The findings support the use of aztreonam in clinical practice for susceptible perinatal infections.